Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 17 of 17 results for omalizumab

  1. Omalizumab for the treatment of severe persistent allergic asthma in children aged 6–11 (TA201)

    This guidance has been updated and replaced by NICE technology appraisal guidance 278.

    Withdrawn guidance

  2. 12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (TA1045)

    Evidence-based recommendations on 12 standard quality house dust mite sublingual lyophilisate (SQ-HDM SLIT; Acarizax) for treating allergic rhinitis and allergic asthma caused by house dust mites.

    Technology appraisal guidance
    Published
    5 March 2025
    View recommendations

    Sections for TA1045